Reduction of Small Fibers of Thoracic Ventral Roots and Neurons of Intermediolateral Nucleus in Parkinson Disease and Dementia with Lewy Bodies

2016 ◽  
Vol 6 (2) ◽  
pp. 325-334 ◽  
Author(s):  
Hiroyuki Hatsuta ◽  
Masaki Takao ◽  
Yuta Nakano ◽  
Akane Nogami ◽  
Akiko Uchino ◽  
...  
Keyword(s):  
Parkinson Disease ◽  
Dementia With Lewy Bodies ◽  
Lewy Bodies ◽  
Ventral Roots ◽  
Intermediolateral Nucleus

scholarly journals Levodopa-induced dyskinesia in dementia with Lewy bodies and Parkinson disease with dementia

2019 ◽  
Vol 10 (2) ◽  
pp. 156-161
Author(s):  
Pierpaolo Turcano ◽  
Cole D. Stang ◽  
James H. Bower ◽  
J. Eric Ahlskog ◽  
Bradley F. Boeve ◽  
...  
Keyword(s):  
Parkinson Disease ◽  
Dementia With Lewy Bodies ◽  
Lewy Bodies ◽  
Population Based ◽  
Olmsted County ◽  
Levodopa Dosage ◽  
Younger Age ◽  
Increased Risk ◽  
Incident Cohort ◽  
Median Interval

ObjectiveTo investigate the frequency of levodopa-induced dyskinesia in dementia with Lewy bodies (DLBs) and Parkinson disease with dementia (PDD) and compare these frequencies with patients with incident Parkinson disease (PD) through a population-based cohort study.MethodsWe identified all patients with DLB, PDD, and PD without dementia in a 1991–2010 population-based parkinsonism-incident cohort, in Olmsted County, Minnesota. We abstracted information about levodopa-induced dyskinesia. We compared patients with DLB and PDD with dyskinesia with patients with PD from the same cohort.ResultsLevodopa use and dyskinesia data were available for 141/143 (98.6%) patients with a diagnosis of either DLB or PDD; 87 (61.7%), treated with levodopa. Dyskinesia was documented in 12.6% (8 DLB and 3 PDD) of levodopa-treated patients. Among these patients, median parkinsonism diagnosis age was 74 years (range: 64–80 years); 63.6%, male. The median interval from levodopa initiation to dyskinesia onset was 2 years (range: 3 months–4 years); the median daily levodopa dosage was 600 mg (range: 50–1,600 mg). Dyskinesia severity led to levodopa adjustments in 5 patients, and all improved. Patients with dyskinesia were diagnosed with parkinsonism at a significantly younger age compared with patients without dyskinesia (p < 0.001). Levodopa dosage was unrelated to increased risk of dyskinesias among DLB and PDD. In contrast, 30.1% of levodopa-treated patients with PD developed dyskinesia. In age-, sex-, and levodopa dosage–adjusted models, Patients with DLB and PDD each had lower odds of developing dyskinesia than patients with PD (odds ratio = 0.42, 95% CI 0.21–0.88; p = 0.02).ConclusionsThe dyskinesia risk for levodopa-treated patients with DLB or PDD was substantially less than for levodopa-treated patients with PD.

Gastrointestinal function in dementia with Lewy bodies: a comparison with Parkinson disease

2019 ◽  
Vol 29 (6) ◽  
pp. 633-638 ◽  
Author(s):  
Hirokazu Doi ◽  
Ryuji Sakakibara ◽  
Masayuki Masuda ◽  
Fuyuki Tateno ◽  
Yosuke Aiba ◽  
...  
Keyword(s):  
Parkinson Disease ◽  
Dementia With Lewy Bodies ◽  
Lewy Bodies ◽  
Gastrointestinal Function

scholarly journals Rapid and ultra-sensitive quantitation of disease-associated α-synuclein seeds in brain and cerebrospinal fluid by αSyn RT-QuIC

2018 ◽  
Vol 6 (1) ◽  
Author(s):  
Bradley R. Groveman ◽  
Christina D. Orrù ◽  
Andrew G. Hughson ◽  
Lynne D. Raymond ◽  
Gianluigi Zanusso ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Parkinson Disease ◽  
Real Time ◽  
Sensitivity And Specificity ◽  
Dementia With Lewy Bodies ◽  
Lewy Bodies ◽  
Diagnostic Sensitivity ◽  
Diagnosis And Treatment ◽  
Specific Detection ◽  
End Point

Abstract The diagnosis and treatment of synucleinopathies such as Parkinson disease and dementia with Lewy bodies would be aided by the availability of assays for the pathogenic disease-associated forms of α-synuclein (αSynD) that are sufficiently sensitive, specific, and practical for analysis of accessible diagnostic specimens. Two recent αSynD seed amplification tests have provided the first prototypes for ultrasensitive and specific detection of αSynD in patients’ cerebrospinal fluid. These prototypic assays require 5–13 days to perform. Here, we describe an improved α-synuclein real time quaking-induced conversion (αSyn RT-QuIC) assay that has similar sensitivity and specificity to the prior assays, but can be performed in 1–2 days with quantitation. Blinded analysis of cerebrospinal fluid from 29 synucleinopathy cases [12 Parkinson’s and 17 dementia with Lewy bodies] and 31 non-synucleinopathy controls, including 16 Alzheimer’s cases, yielded 93% diagnostic sensitivity and 100% specificity for this test so far. End-point dilution analyses allowed quantitation of relative amounts of αSynD seeding activity in cerebrospinal fluid samples, and detection in as little as 0.2 μL. These results confirm that αSynD seeding activity is present in cerebrospinal fluid. We also demonstrate that it can be rapidly detected, and quantitated, even in early symptomatic stages of synucleinopathy.

Relationship between Parkinson disease with dementia and dementia with Lewy bodies

2005 ◽  
Vol 11 (5) ◽  
pp. 305-309 ◽  
Author(s):  
Li Guo ◽  
Masako Itaya ◽  
Masashi Takanashi ◽  
Yoshikuni Mizuno ◽  
Hideo Mori
Keyword(s):  
Parkinson Disease ◽  
Dementia With Lewy Bodies ◽  
Lewy Bodies
Sign in / Sign up

Export Citation Format

Share Document